For Immediate Release

Ellen Scipta and Chris Cowen join the organization as CFO and CCO, respectively, while Todd Martensen transitions from CCO to CSO

SAN DIEGO, Calif., March 26, 2025 – Ascential Medical & Life Sciences, a leader in end-to-end solutions for complex medical and life science devices that provides total commercialization services from ideation to scaled manufacturing, today announced three key executive leadership changes that will play an integral role in positioning the company for its next phase of growth. Ellen Scipta has been appointed Chief Financial Officer (CFO), Todd Martensen has transitioned from Chief Commercial Officer (CCO) to Chief Strategy Officer (CSO), and Christopher Cowen has assumed the role of CCO. This strategic leadership evolution strengthens the company’s ability to execute its vision and further solidifies its place as an industry leader.

As CFO, Ellen will oversee the company’s financial strategy, drive operational efficiencies and support its continued growth within the medical and life sciences sector. She brings more than two decades of experience leading financial operations, transforming organizations and navigating complex business challenges. She has a proven track record of uniting teams to achieve organizational goals and an unwavering commitment to integrity, value and operational excellence. Ellen’s experience spans public, private and consulting sectors including significant tenure in global life sciences and consumer products companies such as Bio-Technie and Best Buy. Prior to joining Ascential Medical & Life Sciences, she was managing director at Riveron Consulting, a national business advisory firm, where she focused on financial planning and analysis (FP&A), financial reporting, financial technology and client solutions. 

“Ellen’s deep financial expertise and energetic leadership style will be invaluable as we continue to scale our operations and identify streamlined ways to support our customers,” said Anupam Girdhar, CEO of Ascential Medical & Life Sciences. “Her strategic vision and get-things-done approach align with our mission of continuing to unlock performance for mission-critical companies.”

Additionally, Todd has transitioned from his role as CCO to CSO to lead the company’s strategic direction and long-term growth initiatives. In this instrumental position, Todd will play a pivotal role in advancing the company’s position as a leader in the medical and life sciences industry by fostering innovation, partnerships, mergers and acquisitions (M&A) and strategic investments while unlocking new market segments and growth areas. For the last two years, Todd has been a vital part of Ascential Medical & Life Sciences’ success. He brings more than three decades of experience in commercial leadership, strategic planning and operations and a strong vision for expansion and innovation. 

“Todd’s passion and commitment to operational excellence has been instrumental in our recent momentum, and we are confident that he will thrive in his new role as CSO,” said Anupam. “His expertise in setting strategic direction and identifying organic and inorganic growth opportunities will help further scale Ascential Medical & Life Sciences and open doors for the company to make an even bigger impact in the healthcare industry.”

As Todd transitions to his new role, Chris Cowen joins Ascential Medical & Life Sciences as the new Chief Commercial Officer (CCO), bringing a strong focus on driving commercial success across all business units. He will play a key role in strengthening customer relationships and ensuring the sales team provides outstanding support to help our partners navigate the challenges of today’s dynamic global market. Chris brings over 30 years of experience in the medical and life sciences sector. Most recently, he served as Chief Commercial Officer at Alveo Technologies. Prior to that, he spent two decades at Thermo Fisher, where he led the commercial organization for the genetic sciences division, driving growth and building sustainable sales models. A seasoned global sales and marketing leader, Chris is known for inspiring teams and delivering outstanding results in complex and competitive markets.

“Chris is a transformative leader with a deep understanding of the medical and life sciences landscape,” said Anupam. “His expertise will be crucial in shaping our commercial strategy and driving significant growth as we expand our global presence. We are excited to welcome him to the team and look forward to the impact he will make.”

For additional information on Ascential Medical & Life Sciences, please visit https://mls.ascentialtech.com/. 

About Ascential Technologies
Ascential Technologies, (formerly known as Burke Porter Group), designs, develops, and automates complex diagnostics, inspection and test processes across medical & life sciences, transportation, and test & measurement systems end markets. The company tackles customers’ most demanding, mission-critical challenges where the cost of failure is high. With more than 70 years of innovation experience, Ascential has a global presence and the expertise of more than 2,300 professionals across 40 locations, helping customers accelerate critical solution innovation, mitigate risk, drive competitive differentiation, and shorten time to market, at scale. The company’s uniqueness lies in its commitment to guiding customers through the entire product life cycle, from ideation to commercialization, where quality and safety matter most. Ascential’s customers include Fortune 100 leaders and disruptive innovators. Learn more at mls.ascentialtech.com. 

Editorial Contacts
Agency:
Brittney Popa
MBE Group on behalf of Ascential Technologies
231-675-1692
[email protected]

Mike Bleau
Industry Scope on behalf of Ascential Technologies
(810) 397-1429
[email protected]